Renal Cell Cancer Update

Dr Jeffrey Bradley from the Emory University School of Medicine in Atlanta, Georgia, and Dr David Spigel from the Sarah Cannon Research Institute in Nashville, Tennessee, discuss the past, present and future management of unresectable Stage III non-small cell lung cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayStageIIINSCLC22).

Dr Sandy Srinivas from Stanford University in California discusses key abstracts across genitourinary cancers presented at the 2022 ASCO annual meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASCOGU22).

Professor Juan Valle from The Christie NHS Foundation Trust in Manchester, United Kingdom, discusses the evolving treatment landscape in biliary tract cancers. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayCholangiocarcinoma22).

Dr Angela DeMichele from the University of Pennsylvania in Philadelphia discusses key abstracts in breast cancer presented at the 2022 ASCO annual meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASCOBreast22).

Dr Adam Brufsky from the UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania, discusses recent data in HER2-low breast cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyToday22HER2LowBC).

Dr Loretta Nastoupil from The University of Texas MD Anderson Cancer Center in Houston, Texas, discusses recent advances and future directions in the treatment of patients with follicular lymphoma. CME information and select publications here (http://www.researchtopractice.com/OncologyToday22FollicularLymphoma).

Dr David O’Malley from The Ohio State University and The James Cancer Center in Columbus, Ohio, discusses trials in ovarian cancer presented at SGO 2022. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostSGO22).

Dr Judy Garber from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent data with PARP inhibitors for breast cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPARPBreast22).

Dr Mark Agulnik from City of Hope in Duarte, California, discusses recent therapeutic advances in soft tissue sarcoma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodaySoftTissue22).

Dr Ajai Chari from the Tisch Cancer Institute Clinical Trials Office in New York discusses recent therapeutic advances in multiple myeloma presented at the 2021 ASH annual meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASHMM22).

Dr Prithviraj Bose from The University of Texas MD Anderson Cancer Center in Houston, Texas, discusses recent therapeutic advances in myeloproliferative neoplasms presented at the 2021 ASH annual meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASHMPN22).

Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha, Nebraska, discusses recent therapeutic advances in Hodgkin and non-Hodgkin lymphomas. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASHLymphoma22).

Dr Andrew Brunner from the Massachusetts General Hospital Cancer Center in Boston, Massachusetts, discusses updates from ASH 2021 on the management of acute myeloid leukemia and myelodysplastic syndromes. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASHAMLMDS22).

Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses current issues in the research and management of localized estrogen receptor-positive breast cancer.   CME information and select publications here (http://www.researchtopractice.com/OncologyTodayERLocalizedBC22).

Dr Peter Hillmen from the University of Leeds in Leeds, England, discusses recent advances in the management of chronic lymphocytic leukemia. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayCLL21/Issue2).

Dr Matthew Davids from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent therapeutic advances in chronic lymphocytic leukemia presented at ASH 2021. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASHCLL22).

Dr Saad Zafar Usmani from the Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent therapeutic advances in transplant-ineligible newly diagnosed multiple myeloma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayMMElderly22).

Dr Evan Yu from the Fred Hutchinson Cancer Research Center in Seattle, Washington, discusses recent therapeutic advances in metastatic castration-resistant prostate cancer CME information and select publications here (http://www.researchtopractice.com/OncologyTodaymCRPC21/Issue2).

Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora, Colorado, discusses recent therapeutic advances in the management of colorectal cancers. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayCRCANAL21/Issue2).

Dr Michael Pishvaian from the Johns Hopkins University School of Medicine in Washington, DC, discusses recent therapeutic advances in pancreatic cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPancreasPARP21).